Mylan Ireland Ltd Drug Patent Portfolio

Mylan Ireland Ltd owns 1 orange book drug protected by 20 US patents Given below is the list of Mylan Ireland Ltd's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11484531 Methods for treating chronic obstructive pulmonary disease 23 Oct, 2039
Active
US12048692 Methods for treating chronic obstructive pulmonary disease 29 Aug, 2039
Active
US8541451 Crystalline freebase forms of a biphenyl compound 25 Aug, 2031
Active
US10550081 Crystalline freebase forms of a biphenyl compound 14 Jul, 2030
Active
US11008289 Crystalline freebase forms of a biphenyl compound 14 Jul, 2030
Active
US11691948 Crystalline freebase forms of a biphenyl compound 14 Jul, 2030
Active
US11858898 Crystalline freebase forms of a biphenyl compound 14 Jul, 2030
Active
US9765028 Crystalline freebase forms of a biphenyl compound 14 Jul, 2030
Active
US7288657 Biphenyl compounds useful as muscarinic receptor antagonists 31 Oct, 2028
Active
US10106503 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
Active
US10343995 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
Active
US11247969 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
Active
US7491736 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
Active
US7521041 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
Active
US7550595 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
Active
US7585879 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
Active
US7910608 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
Active
US8034946 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
Active
US8053448 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
Active
US8273894 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
Active


Given below is the list of recent legal activities going on the following drug patents of Mylan Ireland Ltd.

Activity Date Patent Number
Patent litigations
Change in Power of Attorney (May Include Associate POA) 03 May, 2024 US7585879
Email Notification 03 May, 2024 US7585879
Change in Power of Attorney (May Include Associate POA) 25 Apr, 2024 US7288657
Email Notification 25 Apr, 2024 US7288657
Payment of Maintenance Fee, 12th Year, Large Entity 25 Mar, 2024 US8273894
Notice of Final Determination -Election Required 22 Mar, 2024 US7288657
Notice of Final Determination -Election Required 22 Mar, 2024 US7585879
Patent eCofC Notification 20 Feb, 2024 US11858898
Email Notification 20 Feb, 2024 US11858898
Recordation of Patent eCertificate of Correction 20 Feb, 2024 US11858898
Mail Patent eCofC Notification 20 Feb, 2024 US11858898
Post Issue Communication - Certificate of Correction 31 Jan, 2024 US11858898
Recordation of Patent eGrant 02 Jan, 2024 US11858898
Patent Issue Date Used in PTA Calculation 02 Jan, 2024 US11858898
Mail Patent eGrant Notification 02 Jan, 2024 US11858898


Mylan Ireland Ltd's Family Patents

Mylan Ireland Ltd drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 39.8% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Mylan Ireland Ltd Drug List

Given below is the complete list of Mylan Ireland Ltd's drugs and the patents protecting them.


1. Yupelri

Yupelri is protected by 20 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11484531 Methods for treating chronic obstructive pulmonary disease 23 Oct, 2039
(15 years from now)
Active
US12048692 Methods for treating chronic obstructive pulmonary disease 29 Aug, 2039
(14 years from now)
Active
US8541451 Crystalline freebase forms of a biphenyl compound 25 Aug, 2031
(6 years from now)
Active
US10550081 Crystalline freebase forms of a biphenyl compound 14 Jul, 2030
(5 years from now)
Active
US11008289 Crystalline freebase forms of a biphenyl compound 14 Jul, 2030
(5 years from now)
Active
US11691948 Crystalline freebase forms of a biphenyl compound 14 Jul, 2030
(5 years from now)
Active
US11858898 Crystalline freebase forms of a biphenyl compound 14 Jul, 2030
(5 years from now)
Active
US9765028 Crystalline freebase forms of a biphenyl compound 14 Jul, 2030
(5 years from now)
Active
US7288657 Biphenyl compounds useful as muscarinic receptor antagonists 31 Oct, 2028
(4 years from now)
Active
US10106503 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
(4 months from now)
Active
US10343995 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
(4 months from now)
Active
US11247969 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
(4 months from now)
Active
US7491736 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
(4 months from now)
Active
US7521041 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
(4 months from now)
Active
US7550595 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
(4 months from now)
Active
US7585879 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
(4 months from now)
Active
US7910608 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
(4 months from now)
Active
US8034946 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
(4 months from now)
Active
US8053448 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
(4 months from now)
Active
US8273894 Biphenyl compounds useful as muscarinic receptor antagonists 10 Mar, 2025
(4 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yupelri's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List